These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9407519)

  • 1. Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo.
    Haas M; Kluppel AC; Wartna ES; Moolenaar F; Meijer DK; de Jong PE; de Zeeuw D
    Kidney Int; 1997 Dec; 52(6):1693-9. PubMed ID: 9407519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid.
    Franssen EJ; Moolenaar F; de Zeeuw D; Meijer DK
    Pharm Res; 1993 Jul; 10(7):963-9. PubMed ID: 8378258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat.
    Haas M; Moolenaar F; Meijer DK; de Jong PE; de Zeeuw D
    Clin Sci (Lond); 1998 Nov; 95(5):603-9. PubMed ID: 9791047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme.
    Franssen EJ; van Amsterdam RG; Visser J; Moolenaar F; de Zeeuw D; Meijer DK
    Pharm Res; 1991 Oct; 8(10):1223-30. PubMed ID: 1796038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.
    Kok RJ; Grijpstra F; Walthuis RB; Moolenaar F; de Zeeuw D; Meijer DK
    J Pharmacol Exp Ther; 1999 Jan; 288(1):281-5. PubMed ID: 9862782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases.
    Dolman ME; van Dorenmalen KM; Pieters EH; Lacombe M; Pato J; Storm G; Hennink WE; Kok RJ
    J Control Release; 2012 Feb; 157(3):461-8. PubMed ID: 21911014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
    Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
    J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization and in vitro evaluation of triptolide-lysozyme conjugate for renal targeting delivery of triptolide.
    Zheng Q; Gong T; Sun X; Zhang ZR
    Arch Pharm Res; 2006 Dec; 29(12):1164-70. PubMed ID: 17225468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
    Franssen EJ; Koiter J; Kuipers CA; Bruins AP; Moolenaar F; de Zeeuw D; Kruizinga WH; Kellogg RM; Meijer DK
    J Med Chem; 1992 Apr; 35(7):1246-59. PubMed ID: 1560438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.
    Dolman ME; Harmsen S; Pieters EH; Sparidans RW; Lacombe M; Szokol B; Orfi L; Kéri G; Storm G; Hennink WE; Kok RJ
    Int J Nanomedicine; 2012; 7():417-33. PubMed ID: 22334775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicity.
    Haas M; Moolenaar F; Elsinga A; Van der Wouden EA; de Jong PE; Meijer DK; de Zeeuw D
    J Drug Target; 2002 Feb; 10(1):81-9. PubMed ID: 11996090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of naproxen covalently linked to HSA to sinusoidal cell types of the liver.
    Melgert BN; Wartna E; Lebbe C; Albrecht C; Molema G; Poelstra K; Reichen J; Meijer DK
    J Drug Target; 1998; 5(5):329-42. PubMed ID: 9771615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.
    Kok RJ; Haverdings RF; Grijpstra F; Koiter J; Moolenaar F; de Zeeuw D; Meijer DK
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1139-43. PubMed ID: 12023548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentials and limitations of the low-molecular-weight protein lysozyme as a carrier for renal drug targeting.
    Haverdings RF; Haas M; Greupink AR; de Vries PA; Moolenaar F; de Zeeuw D; Meijer DK
    Ren Fail; 2001; 23(3-4):397-409. PubMed ID: 11499555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells.
    Zhang Z; Zheng Q; Han J; Gao G; Liu J; Gong T; Gu Z; Huang Y; Sun X; He Q
    Biomaterials; 2009 Mar; 30(7):1372-81. PubMed ID: 19100618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme.
    Kok RJ; Haas M; Moolenaar F; de Zeeuw D; Meijer DK
    Ren Fail; 1998 Mar; 20(2):211-7. PubMed ID: 9574445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules.
    Franssen EJ; Jansen RW; Vaalburg M; Meijer DK
    Biochem Pharmacol; 1993 Mar; 45(6):1215-26. PubMed ID: 8466542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate.
    Albrecht C; Melgert BN; Reichen J; Poelstra K; Meijer DK
    J Drug Target; 1998; 6(2):105-17. PubMed ID: 9886235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.
    Prakash J; van Loenen-Weemaes AM; Haas M; Proost JH; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
    Drug Metab Dispos; 2005 May; 33(5):683-8. PubMed ID: 15673598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis.
    Prakash J; Sandovici M; Saluja V; Lacombe M; Schaapveld RQ; de Borst MH; van Goor H; Henning RH; Proost JH; Moolenaar F; Këri G; Meijer DK; Poelstra K; Kok RJ
    J Pharmacol Exp Ther; 2006 Oct; 319(1):8-19. PubMed ID: 16807361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.